-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to the website of the State Drug Administration, on December 8, the State Drug Administration approved Tengsheng Huachuang Medical Technology (Beijing) Co.
, Ltd.
's new coronavirus neutralizing antibody combined therapy drug Ambavirimab Injection (BRII-196) ) And Romisvirimab injection (BRII-198) registration application
.
This is China's first approved new coronavirus neutralizing antibody combination therapy with independent intellectual property rights
.
, Ltd.
's new coronavirus neutralizing antibody combined therapy drug Ambavirimab Injection (BRII-196) ) And Romisvirimab injection (BRII-198) registration application
.
This is China's first approved new coronavirus neutralizing antibody combination therapy with independent intellectual property rights
.
According to the relevant provisions of the " Drug Administration Law" and in accordance with the special drug approval procedures, the State Drug Administration will conduct emergency review and approval, and approve the combination of the above two drugs for the treatment of mild and common types with progression to severe (including hospitalization or death) Adults and adolescents (12-17 years old, weight ≥40kg) with high-risk factors, patients with new coronavirus infection (COVID-19)
.
Among them, adolescents (12-17 years old, weight ≥40kg) are eligible for conditional approval
.
.
Among them, adolescents (12-17 years old, weight ≥40kg) are eligible for conditional approval
.
According to the website of the State Drug Administration, on December 8, the State Drug Administration approved Tengsheng Huachuang Medical Technology (Beijing) Co.
, Ltd.
's new coronavirus neutralizing antibody combined therapy drug Ambavirimab Injection (BRII-196) ) And Romisvirimab injection (BRII-198) registration application
.
This is China's first approved new coronavirus neutralizing antibody combination therapy with independent intellectual property rights
.
, Ltd.
's new coronavirus neutralizing antibody combined therapy drug Ambavirimab Injection (BRII-196) ) And Romisvirimab injection (BRII-198) registration application
.
This is China's first approved new coronavirus neutralizing antibody combination therapy with independent intellectual property rights
.
According to the relevant provisions of the " Drug Administration Law" and in accordance with the special drug approval procedures, the State Drug Administration will conduct emergency review and approval, and approve the combination of the above two drugs for the treatment of mild and common types with progression to severe (including hospitalization or death) Adults and adolescents (12-17 years old, weight ≥40kg) with high-risk factors, patients with new coronavirus infection (COVID-19)
.
Among them, adolescents (12-17 years old, weight ≥40kg) are eligible for conditional approval
.
.
Among them, adolescents (12-17 years old, weight ≥40kg) are eligible for conditional approval
.
According to the website of the State Drug Administration, on December 8, the State Drug Administration approved Tengsheng Huachuang Medical Technology (Beijing) Co.
, Ltd.
's new coronavirus neutralizing antibody combined therapy drug Ambavirimab Injection (BRII-196) ) And Romisvirimab injection (BRII-198) registration application
.
This is China's first approved new coronavirus neutralizing antibody combination therapy with independent intellectual property rights
.
, Ltd.
's new coronavirus neutralizing antibody combined therapy drug Ambavirimab Injection (BRII-196) ) And Romisvirimab injection (BRII-198) registration application
.
This is China's first approved new coronavirus neutralizing antibody combination therapy with independent intellectual property rights
.
According to the relevant provisions of the " Drug Administration Law" and in accordance with the special drug approval procedures, the State Drug Administration will conduct emergency review and approval, and approve the combination of the above two drugs for the treatment of mild and common types with progression to severe (including hospitalization or death) Adults and adolescents (12-17 years old, weight ≥40kg) with high-risk factors, patients with new coronavirus infection (COVID-19)
.
Among them, adolescents (12-17 years old, weight ≥40kg) are eligible for conditional approval
.
Medicine, medicine, medicine .
Among them, adolescents (12-17 years old, weight ≥40kg) are eligible for conditional approval
.
